Psychiatry · AntidepressantRegulatory Approvalregulatorymid-term

FDA Approval Status Update for Doxepin Hydrochloride by Mylan

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Mylan17 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/24/2026, 6:03:17 AM

Assessment confidence: 84% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval status for Mylan's supplemental application for Doxepin Hydrochloride is significant as it enhances Mylan's competitive position in the antidepressant market. This approval could lead to increased market share and influence pricing strategies against branded competitors. Regulatory context from FDA (FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (17 high-relevance).

Strategic Assessment

Mylan could leverage this approval to expand its market share and potentially impact pricing strategies against branded competitors. The strongest clinical anchor is Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia (ClinicalTrials.gov), moderate corpus alignment. In Psychiatry · Antidepressant, 8 regulatory and 4 competitive items passed relevance filtering for Mylan.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approves Ferric Carboxymaltose for Mylan's ANDA217076 (Humanexa Signals) — entity match (mylan). Secondary pressure from FDA Grants Approval for Ferric Carboxymaltose by Mylan Labs. This approval status may enhance Mylan's competitive position in the antidepressant market, particularly for generic formulations.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL) (FDA). Entity match (mylan); Regulatory pathway relevance (nda). The approval status indicates compliance with FDA standards, but ongoing monitoring is required to ensure successful market launch and adherence to regulatory requirements.

Key Risks

Elevated medium regulatory exposure for Mylan could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development) could weigh on Mylan through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community) could weigh on Mylan through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Mylan's ability to market Doxepin Hydrochloride could lead to increased revenue through expanded market share in the generic antidepressant segment, potentially affecting overall pricing dynamics.
Upside for Mylan may improve if Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD (ClinicalTrials.gov) delivers favorable follow-through.
Mylan could leverage this approval to expand its market share and potentially impact pricing strategies against branded competitors.

What Would Change This Assessment

This becomes more urgent if Monitor for further updates on the approval process and any market launch announcements from Mylan.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (mylan); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DOXEPIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (doxepin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (mylan); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DICYCLOMINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MOXIFLOXACIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Menstrual Status, Anesthetic Consumption, and PONV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Approves Ferric Carboxymaltose for Mylan's ANDA217076
Humanexa Signalshigh relevance
Entity match (mylan)
FDA Grants Approval for Ferric Carboxymaltose by Mylan Labs
Humanexa Signalshigh relevance
Entity match (mylan)
FDA Grants Priority Review for Novartis' Fabhalta (Ipacopan Hydrochloride)
Humanexa Signalshigh relevance
Sponsor/company relevance (Novartis)
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Mylan
Doxepin Hydrochloride

Commercial impact

medium

Mylan's ability to market Doxepin Hydrochloride could lead to increased revenue through expanded market share in the generic antidepressant segment, potentially affecting overall pricing dynamics.

Regulatory impact

medium

The approval status indicates compliance with FDA standards, but ongoing monitoring is required to ensure successful market launch and adherence to regulatory requirements.

What to watch

Monitor for further updates on the approval process and any market launch announcements from Mylan.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.